Adults with obesity or type 2 diabetes who take a weekly 12 mg dose of retatrutide are way more likely—over 70 times more—to lose at least 15% of their body weight in less than a year compared to...
0
57
Evidence from Studies
Supporting (0)
0
Community contributions welcome
No supporting evidence found
Contradicting (1)
57
Community contributions welcome
57
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Systematic Review With Meta-Analysis
Human
2025Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.